

Mail Stop 3561

May 8, 2006

Mr. Keith Berman  
Chief Financial Officer  
instaCare Corp.  
2660 Townsgate Road  
Suite 300  
Westlake Village, CA 91361

**Re: instaCare Corp.  
Form 8-K Item 4.02  
Filed April 12, 2006  
File No. 000-33187**

Dear Mr. Berman:

We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with more information so we may better understand your disclosure. After reviewing this information, we may raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

1. We have reviewed your disclosure surrounding the impairment of Pharma Tech Solutions as it relates to the merger with CareGeneration, Inc. Please provide a detailed discussion of how the company determined the impairment occurred in March 2005. In a SEC comment letter dated December 7, 2005, the SEC requested the company tell us in detail how the company accounted for the acquisition of CareGeneration Inc. in the financial statements. The company was requested to disclose how they recorded this transaction (e.g. business combination, etc.) and provide a narrative discussion discussing the terms of the

transaction. It was requested that you cite the specific authoritative literature you used to support your accounting treatment. Please provide a detailed discussion of how the company addressed this outstanding comment when determining the amount and timing of the impairment of Pharm Tech Solutions.

2. Please amend your filing to state whether the audit committee, or the board of directors in the absence of an audit committee, or authorized officer or officers, discussed with the independent accountant the matters disclosed in the filing.
3. When you amend your periodic reports to file your restated financial statements, describe the effect of the restatement on the officers' conclusions regarding the effectiveness of the company's disclosure controls and procedures. See Item 307 of Regulation S-K or Regulation S-B. If the officers' conclude that the disclosure controls and procedures were effective, despite the restatement, describe the basis for the officers' conclusions.

As appropriate, please amend your filing and respond to these comments within five business days or tell us when you will provide us with a response. You may wish to provide us with marked copies of the amendment to expedite our review. Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested information. Detailed cover letters greatly facilitate our review. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information required under the Securities Exchange Act of 1934 and that they have provided all information investors require for an informed investment decision. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in writing, a statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

If you have any questions, please call Angela Halac, Staff Accountant at (202) 551-3398.

Sincerely,

Angela J. Halac  
Staff Accountant  
Office of Emerging Growth  
Companies